Q-State Biosciences, Inc.
Cambridge, MA · Biotech · Acquired
Antisense oligonucleotide (ASO) therapeutic targeting FUS gene mutations in ALS
qstatebio.com →- Grants
- $22M
- 32 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 5 granted · 35 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Optopatch: high-throughput all-optical electrophysiology for neural recording | $329,000 | |
| Federal grant | Department of Health and Human Services · Phase II · High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity. | $602,645 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Develop predictive human cardiomyocyte-based all optical assay for cardiotoxicity | $824,331 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · High throughput all optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity | $972,225 | |
| Federal grant | Department of Health and Human Services · Phase II · Optopatch: high-throughput all-optical electrophysiology | $676,626 | |
| Federal grant | Department of Health and Human Services · Phase I · Scalable, all-optical assays of synaptic function and plasticity | $764,645 | |
| Federal grant | Department of Health and Human Services · Phase II · High-throughput, all-optical assay in human cardiomyoctes for clinically relevant prediction of drug induced cardiotoxity. | $369,580 | |
| Federal grant | Department of Health and Human Services · Phase I · All-optical electrophysiology in brain slice for drastically increased throughput | $429,501 | |
| Federal grant | Department of Health and Human Services · Phase II · Optopatch: high-throughput all-optical electrophysiology | $318,023 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid, in vitro phenotyping of monogenic neurological disorders using CRISPRi and high-throughput all-optical electrophysiology. | $345,471 | |
| Federal grant | Department of Health and Human Services · Phase I · Scalable, all-optical assays of synaptic function and plasticity | $344,855 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing an in vitro model for cancer pain using all-optical electrophysiology | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase II · An all-optical electrophysiology platform for the discovery of pain therapeutics | $222,370 | |
| Federal grant | Department of Health and Human Services · Phase I · All-optical electrophysiology in brain slice for drastically increased throughput | $297,542 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid, in vitro phenotyping of monogenic neurological disorders using CRISPRi and high-throughput all-optical electrophysiology. | $550,626 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing an in vitro model for cancer pain using all-optical electrophysiology | $92,923 | |
| Federal grant | Department of Health and Human Services · Phase II · Scalable, all-optical assays of synaptic function and plasticity | $2,262,081 | |
| Federal grant | Department of Health and Human Services · Phase II · Optopatch:high-throughput all-optical electrophysiology | $2,088,693 | |
| Federal grant | Department of Health and Human Services · Phase II · An all-optical electrophysiology platform for the discovery of pain therapeutics | $1,732,886 | |
| Federal grant | Department of Health and Human Services · Phase II · A phenotypic screen for compounds that differentially affect excitatory and inhibitory neuronal signaling | $585,093 | |
| Federal grant | Department of Health and Human Services · Phase I · Anti-sense oligonucleotide platform for rare genetic diseases of the nervous system | $343,037 | |
| Federal grant | Department of Health and Human Services · Phase I · Functional drug fingerprinting with all-optical electrophysiology | $885,237 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting ALS-linked FUS with allele-specific antisense oligonucleotides | $236,911 | |
| Federal grant | Department of Health and Human Services · Phase II · Scalable, all-optical assays of synaptic function and plasticity | $771,167 | |
| Federal grant | Department of Health and Human Services · Phase II · Optopatch:high-throughput all-optical electrophysiology | $724,571 | |
| Federal grant | Department of Health and Human Services · Phase II · An all-optical electrophysiology platform for the discovery of pain therapeutics | $1,000,946 | |
| Federal grant | Department of Health and Human Services · Phase I · Functional drug fingerprinting with all-optical electrophysiology | $434,945 | |
| Federal grant | Department of Health and Human Services · Phase I · An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies | $451,550 | |
| Federal grant | Department of Health and Human Services · Phase II · Scalable, all-optical assays of synaptic function and plasticity | $713,034 | |
| Federal grant | Department of Health and Human Services · Phase I · An antisense oligonucleotide therapy for KCNT1 based epileptic encephalopathies | $76,089 | |
| Federal grant | Department of Health and Human Services · Phase II · Functional drug fingerprinting with all-optical electrophysiology | $1,296,058 | |
| Federal grant | Department of Health and Human Services · Phase II · Ultra-high-throughput plate reader for drug discovery using all-optical electrophysiology | $475,561 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2870 | Nutcracker Therapeutics | — | $172M |
| 2871 | REDVAULT BIOSCIENCES LP | — | — |
| 2872 | Vertex Pharmaceuticals | — | — |
| 2873 | Q-State Biosciences, Inc. | — | — |
| 2874 | NEUCORE BIO, INC. | — | — |
| 2875 | PROMILEAD, LLC | — | — |
| 2876 | LIBREDE | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Diagnostic Methods For Neural Disordersgranted
- Optogenetics Microscopegranted
- Diagnostic Methods For Neural Disordersgranted
- Cardiotoxicity Screening Methodsgranted
- Synaptic Vesicle Cycling Assays And Systemsapplication
- Systems And Methods For Assessing Inter-cell Communicationapplication
- Diagnostic Methods For Neural Disordersgranted
- Diagnostic Methods For Neural Disordersapplication
- Analysis Of Compounds For Pain And Sensory Disordersapplication
- Models For Parkinson's Disease Studiesapplication
- UBE3A Antisense Therapeuticsapplication
- Optical Plate Controller And Readerapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.